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Abstract
Platelets contribute to vessel formation through the release of angiogenesis-modulating factors stored in their a-granules.
Galectins, a family of lectins that bind b-galactoside residues, are up-regulated in inflammatory and cancerous tissues,
trigger platelet activation and mediate vascularization processes. Here we aimed to elucidate whether the release of
platelet-derived proangiogenic molecules could represent an alternative mechanism through which galectins promote
neovascularization. We show that different members of the galectin family can selectively regulate the release of angiogenic
molecules by human platelets. Whereas Galectin (Gal)-1, -3, and -8 triggered vascular endothelial growth factor (VEGF)
release, only Gal-8 induced endostatin secretion. Release of VEGF induced by Gal-8 was partially prevented by COX-1, PKC,
p38 and Src kinases inhibitors, whereas Gal-1-induced VEGF secretion was inhibited by PKC and ERK blockade, and Gal-3
triggered VEGF release selectively through a PKC-dependent pathway. Regarding endostatin, Gal-8 failed to stimulate its
release in the presence of PKC, Src and ERK inhibitors, whereas aspirin or p38 inhibitor had no effect on endostatin release.
Despite VEGF or endostatin secretion, platelet releasates generated by stimulation with each galectin stimulated angiogenic
responses in vitro including endothelial cell proliferation and tubulogenesis. The platelet angiogenic activity was
independent of VEGF and was attributed to the concerted action of other proangiogenic molecules distinctly released by
each galectin. Thus, secretion of platelet-derived angiogenic molecules may represent an alternative mechanism by which
galectins promote angiogenic responses and its selective blockade may lead to the development of therapeutic strategies
for angiogenesis-related diseases.
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Introduction
In the normal adult, angiogenesis, defined as the growth of new
blood vessels from preexisting capillaries, is mostly limited to
wound healing, pregnancy, and uterine cycling. This process is
regulated by a continuous interplay of stimulators and inhibitors
that tightly control the normally quiescent capillary vasculature,
and their imbalance contributes to numerous malignant, ischemic,
and immune disorders [1].
Emerging evidence implicates a key role for platelets in site-
specific neovascularization at ischemic tissues and the tumor
microenvironment as they are major storage and delivery vehicles
for pro- and antiangiogenic growth factors including vascular
endothelial growth factor (VEGF), endostatin, and thrombospon-
din-1 (TSP-1), and cytokines and chemokines, such as stromal-
derived factor 1 a (SDF-1a) and IL-8 among others. These
proteins are stored together with coagulation factors in platelet a-
granules, which upon activation can degranulate and influence the
local angiogenic response [2,3]. The recent demonstration of
separate packaging of these proteins into morphologically distinct
populations of a-granules in megakaryocytes and platelets [4,5,6],
and their differential release based on selective engagement of
platelet receptors provides mechanism by which platelets can
locally and sequentially modulate angiogenesis [7,8,9,10].
Galectins constitute a family of animal lectins that bind b-
galactoside residues through their carbohydrate recognition
domains (CRD). According to their structure, galectins are
classified into three groups: I) ‘‘proto-type’’ galectins, containing
a single CRD including galectin (Gal) -1, -2, -7, -10, -13, and -14,
II) chimera-type galectins which contain a single CRD and a large
amino-terminal non-lectin domain with Gal-3 being its only
representative, and III) tandem-repeat type galectins which have
two CRD linked by a peptide sequence of variable length and
include Gal-4, -8, -9, and -12 [11]. Galectins are expressed in a
wide variety of cells and tissues and play an important role in
cellular mechanisms including cell signaling, proliferation, migra-
tion, apoptosis, and mRNA splicing [12]. Galectins are also
associated with different pathologies such as allergies, autoimmune
diseases, atherosclerosis, infectious processes, and cancer
[13,14,15,16]. In fact, most of these lectins are up-regulated in
several types of tumors and this feature correlates with tumor
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progression, aggressiveness and acquisition of a metastatic
phenotype [16,17,18]. In addition, increasing evidence indicates
that these proteins are also involved in the pathogenesis of
cardiovascular diseases [13]. Recent work from our laboratory has
shown that both soluble and immobilized Gal-1 and Gal-8 bind
and activate platelets, promoting adhesion, aggregation and
granule secretion [19,20,21,22].
A growing body of experimental evidence suggest that galectins,
mainly Gal-1, -3 and -8, are directly involved in angiogenesis as
they induce endothelial cell proliferation, chemotaxis, in vitro
capillary tube formation, and in vivo neovascularization
[23,24,25,26]. Particularly, the Gal-1-N-glycan axis can link
tumor hypoxia to vascularization [26] and promotes VEGF-like
signals in tumors that are refractory to anti-VEGF therapy [27].
As platelet activation is stimulated by structurally different
galectins, in this study we aimed to elucidate whether the release of
platelet-derived proangiogenic molecules represents an additional
mechanism by which these lectins promote neovascularization.
We found that while all three galectins triggered VEGF release,
only Gal-8 induced endostatin secretion. However, despite
selective release of platelet-derived angiogenic molecules, platelets
stimulated by Gal-1, -3 and -8 promoted angiogenic functional
responses. Thus, secretion of platelet-derived angiogenic molecules
represents an alternative mechanism underlying the proangiogenic
activity of galectins.
Materials and Methods
Reagents
Endostatin and VEGF ELISA kits, and Human angiogenesis
Antibody Array G Series 1000 were from Raybiotech, Inc.
(Norcross, GA, USA). Go¨-6983, PP1, SB-203580 and U-0126
were from Enzo Life Sciences International, Inc. (San Diego, CA,
USA). Recombinant human Gal-1 was produced essentially as
described [28]. The recombinant protein was purified by affinity
chromatography on an asialofetuin-agarose column and stored at
220uC. Lipopolysaccharide content of the purified samples was
tested using a Gel Clot Limulus Test (Cape Cod., East Falmouth,
MA, USA). Human Gal-3-coding DNA sequence was modified to
improve its expression in bacteria and a His tag was included to
favor purification. The sequence was submitted for synthesis
(GeneScript) and the resulting gene subcloned into pTrcHisB
(Invitrogen). Recombinant human Gal-8 (M isoform) was obtained
as described previously [20]. Recombinant human Gal-3 and
mouse gal-1-8-1 chimera were produced as described previously
[29]. Growth factor-reduced Matrigel was obtained from Becton
Dickinson Biosciences (Bedford, MA, USA). MTT [3-(4,5-
dimethylthiaxol-2-yl)-2,5-diphaenyltetrazolium bromide] was from
Promega Corporation (Madison, WI, USA). Recombinant VEGF-
A, goat anti human VEGFR2/KDR/Flk-1, mouse anti human
VEGF-A neutralizing antibody, and the corresponding irrelevant
IgGs were purchased from R&D Systems (Minneapolis, MN,
USA). Rabbit anti-human EGF neutralizing antibody and control
IgG were obtained from Cell Signaling Technology (Danvers,
MA, USA).
Preparation of Human Platelets
Blood samples were obtained from healthy donors who had not
taken nonsteroidal antiinflammatory drugs in the 10 days before
sampling. This study was conducted according to the principles of
the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the National Academy of Medicine,
Buenos Aires, Argentina. All patients provided written informed
consent for the collection of samples and subsequent analysis.
Blood was drawn directly into plastic tubes containing sodium
citrate (3.8%). Platelet rich plasma (PRP) was obtained by
centrifugation of the blood samples (1806g for 10 min). For
washed platelet (WP) suspensions, PRP was centrifuged in the
presence of prostacyclin (PGI2) (75 nM) (8906g for 10 min), and
the platelets were washed in washing buffer (140 mM NaCl,
10 mM NaHCO3, 2.5 mM KCl, 0.5 mM Na2HPO4, 1 mM
MgCl2, 22 mM sodium citrate, 0.55 mM glucose, 0.35% BSA, pH
Figure 1. Gal-1, Gal-3 and Gal-8 differentially control the release of VEGF and endostatin by platelets. A) WPs were stimulated with
different concentrations of Gal-1, -3 or -8 for 5 min (n = 4; *P,0.05 vs. unstimulated). B) WPs (500 ml at 46108/ml) were lysed with Triton X100 (0.1%)
and sonicated (n = 4). The amounts of VEGF and endostatin in supernatants were quantified by ELISA.
doi:10.1371/journal.pone.0096402.g001
Angiogenesis Mediated by Galectin-Treated Platelets
PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e96402
6.5). Finally, platelets were resuspended in Tyrode’s buffer
(134 mM NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.34 mM
Na2HPO4, 1 mM MgCl2, 10 mM HEPES, 5 mM glucose,
0.35% BSA, pH 7.4) at a concentration of 46108/ml, unless
otherwise stated. CaCl2 (1 mM) was added 1 min before platelet
stimulation.
ELISA Assays for VEGF and Endostatin Release
Briefly, WPs (500 ml at 46108/ml) were stimulated with Gal-1, -
3 or -8 for 5 min. Cell suspensions were centrifuged twice (first at
11006g for 5 min and then at 93006g for 5 min) in the presence
of PGI2 (75 nM) and supernatants were stored at 280uC until
assayed. In some experiments, WPs were incubated for 30 min
before stimulation with aspirin (ASA, 500 mM), or with specific
inhibitors of PKC (Go¨-6983, 1 mM), Src (PP1, 5 mM), p38 (SB-
203580, 25 mM) and pERK (U-0126, 10 mM). The concentrations
of the inhibitors were selected from pilot studies and were the
minimal that completely suppressed phosphorylation of the
specific target proteins as previously described [30]. The
concentration of ASA used was the minimal that abrogated
arachidonic acid-induced platelet aggregation. To obtain platelet
lysates, platelet pellets were suspended with distilled in H2O in
presence of Triton X100 (0.1%) and cells were hydrolyzed by
sonication. Ionic concentration was restored by addition of
Tyrode’s buffer (10X) and supernatants were obtained. Release
of VEGF and endostatin was measured by using commercial
ELISA kits according to the manufacturer’s instructions.
Human Angiogenic Factors Array
WPs (500 ml at 46108/ml) were stimulated with Gal-1, -3 or -8
for 5 min. Cell suspensions were centrifuged twice (first at 11006g
for 5 min and then at 93006g for 5 min) in the presence of PGI2
Figure 2. Differential release of VEGF and endostatin is independent of the kinetics of incubation or structural differences among
galectins. A) WPs were pre-incubated in the absence (none) or the presence of sucrose (50 mM) or lactose (50 mM) for 30 min and then stimulated
with Gal-1 (5 mM), Gal-3 (5 mM), or Gal-8 (1 mM) during 5 min. B) WPs were stimulated with Gal-1 (5 mM) or Gal-3 (5 mM) under stirring conditions for
different intervals of time during 60 min. C) WPs were stimulated with different concentrations of a Gal-1 chimera (G1-G1) for 10 min (n = 3; *P,0.05
vs. unstimulated).
doi:10.1371/journal.pone.0096402.g002
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(75 nM) and supernatants were stored at 280uC until assayed.
Release of angiogenic factors was measured by using commercial
array kits according to the manufacturer’s instructions.
Endothelial Cell Culture
Human microvascular endothelial cells 1 (HMEC-1) were
obtained from the Center of Disease Control and Prevention
(CDC, Atlanta, USA). Cells were grown in RPMI supplemented
with fetal bovine serum (10%), L-glutamine (2 mM) and strepto-
mycin (100 mg/ml), and penicillin (100 U/ml) at 37uC in a
humidified 5% CO2 incubator. In selected experiments
VEGFR2/KDR was blocked with an anti-VEGFR2 neutralizing
monoclonal antibody. Some experiments were also performed in
the presence of VEGF-A or EGF receptor (EGFR) neutralizing
antibodies.
Endothelial Cell Proliferation
Cell proliferation was determined by using the MTT [3-(4,5-
dimethylthiaxol-2-yl)-2,5-diphaenyltetrazolium bromide] assay.
Briefly, HMEC-1 (250 ml at 2.56104/well) were incubated in
48-well plates with sucrose (50 mM) or lactose (50 mM) for 30 min
in the presence or absence of the VEGFR2 neutralizing antibody
(2 mg/ml). The medium was then aspirated and cells were
incubated with platelet supernatants (250 ml) previously stimulated
with galectins or control medium without platelets supplemented
with penicillin/streptomycin and polymyxin (7 mg/ml). Positive
and negative controls included Tyrode’s buffer with or without
VEGF (20 ng/ml). After 18 h of incubation, MTT was added to
each well, and cells were further incubated for 3 h at 37uC. Stop
solution was added and aliquots of each well were transferred to a
96-well plate and absorbance at 570 nm was measured. The
number of cells was extrapolated from a concentration-cell curve
performed for each experiment [30].
In vitro Tube Formation Assay
Prechilled 48-well microtiter plates were coated with growth
factor-reduced Matrigel for 2 h at 37uC. HMEC-1 (2.56104) in
Tyrode’s were loaded in each well, preincubated with sucrose
(50 mM) or lactose (50 mM) in the presence or absence of a
neutralizing anti-VEGFR2 antibody (2 mg/ml), anti-VEGF-A
(2 mg/ml), or anti-EGFR (20 mg/ml), for 30 min, and then
incubated in the presence of VEGF (20 ng/ml) or EGF (20 ng/
ml) (positive controls), or platelet supernatants obtained after
stimulation with galectins supplemented with polymyxin (7 mg/ml)
for 18 h. Tube formation was analyzed under an inverted light
microscope, and the number of branch points in four non-
overlapping fields was determined [30].
Statistical Analysis
The results are expressed as mean 6 SEM and were analyzed
by one-way analysis of variance followed by Newman-Keuls
multiple comparison test to determine significant differences
between groups. A P value lower than 0.05 was considered
statistically significant.
Results
Differential Release of VEGF and Endostatin Induced by
Gal-1, -3 and -8
Release of angiogenesis-modulating factors from platelet gran-
ules is one of the mechanisms by which platelets can modulate
vessel formation [3]. As galectins can stimulate both neovascular-
ization and platelet activation, we examined whether representa-
tive members of the three subfamilies of galectins including Gal-1
(‘proto-type’), Gal-3 (‘chimera-repeat’) or Gal-8 (‘tandem-repeat’)
can trigger the release of platelet-derived molecules that promote
or inhibit angiogenesis such as VEGF or endostatin, respectively.
We found that while Gal-8 induced the secretion of VEGF and
endostatin, Gal-1 and -3 only promoted the release of VEGF. Of
note, even at high concentrations (up to 10 mM), Gal-1 and -3
failed to induce endostatin secretion (Figure 1A). Based on EC50
values, we found that Gal-8 induced higher secretion of VEGF
(0.2560.05 mM) than Gal-1 (0.5060.05 mM) or Gal-3
(1.060.3 mM).
The total amount of intraplatelet VEGF and endostatin was
measured in platelet lysates (Figure 1B). Platelet activation induced
by each galectin led to the release of 50% of the stored VEGF,
whereas Gal-8 induced the secretion of 75% of total endostatin.
The secretion of VEGF induced by each galectin as well as the
secretion of endostatin induced by Gal-8 were completely
prevented by lactose, a galectin-specific competitor, but not by
sucrose, suggesting that these effects involved recognition of glycan
residues on the platelet surface (Figure 2A). To examine whether
the selective release of VEGF and endostatin induced by Gal-1
and -3 could be associated with differences in the kinetics of
platelet stimulation, treatment was extended from 5 to 60 min.
Moreover, in order to induce the maximal release of granule
cargo, these assays were performed under stirring. Under these
conditions, VEGF release was slightly enhanced by galectins;
however Gal-1 and Gal-3 still failed to induce endostatin secretion
(Figure 2B). A possible explanation for the differential release of
endostatin after platelet stimulation with Gal-1, -3 or -8 might rely
on the structural differences between the three lectins. To test this
hypothesis, the secretion of angiogenesis-related molecules was
Figure 3. Different signaling pathways mediate the release of
VEGF and endostatin induced by individual galectins. WPs were
incubated with specific inhibitors of cyclooxygenase-1 (ASA, 500 mM),
p38 (SB-203580, 25 mM), PKC (Go¨-6983, 1 mM), Src (PP1, 5 mM), or pERK
(U-0126, 10 mM) for 30 min. Then, platelets were stimulated with the
EC50 of Gal-1 (0.5 mM), Gal-3 (1 mM) and Gal-8 (0.25 mM) for 5 min.
Results are expressed as percentage of inhibition relative to similar
treatment without inhibitor (n = 3; *P,0.05).
doi:10.1371/journal.pone.0096402.g003
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Figure 4. Platelets stimulated by galectins trigger endothelial cell proliferation and capillary-like tube formation. HMEC-1 were
preincubated in 48-well plates in the presence of lactose (50 mM), and with anti-VEGFR2, anti-VEGF-A (2 mg/ml), goat or mouse irrelevant IgGs during
30 min. Since proliferation or capillary tube formation were not modify by the different IgGs we only show the values obtained in the absence of
antibodies. Then, cells were incubated during 18 h with VEGF (20 ng/ml) (positive control) or with supernatants from platelets that were
unstimulated or stimulated with the minimal concentration of galectin to induce maximal VEGF release. A) Endothelial cell proliferation was
determined by addition of MTT reagent. Reaction was stopped and the absorbance was determined at 570 nm. B) Tube formation in Matrigel-coated
wells was analyzed under an inverted light microscope, and the number of branch points in four non-overlapping fields was determined. The
photographs show one individual field of endothelial cells incubated with or without platelet supernatants (n = 4; *P,0.05 vs. unstimulated,#P,0.05
vs. without anti-VEGFR2 mAb).
doi:10.1371/journal.pone.0096402.g004
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induced with a protein chimera designed by connecting two
sequences of full-length Gal-1 with the linker peptide from Gal-8L
isoform, resulting in a combination of the Gal-1 CRD sequence
with the Gal-8 dimeric structure. Like Gal-1, the chimeric lectin
failed to induce endostatin release suggesting that the dissimilar
responses exerted by galectins are not due to their structural
composition but probably to the specific CRDs (Figure 2C).
The Release of VEGF and Endostatin Induced by Galectins
is Regulated by different Signaling Pathways
To investigate the intracellular signals triggered by galectins to
induce VEGF and endostatin release, in the next set of
experiments platelet stimulation was performed in the presence
of specific inhibitors of the major signaling pathways involved in
platelet granule secretion including cyclooxygenase (aspirin), p38
Figure 5. Gal-1, -3 or -8 induce a differential pattern of angiogenic regulators release in platelets. A) WPs were stimulated with Gal-1
(5 mM), Gal-3 (5 mM) or Gal-8 (1 mM) for 5 min. The release of angiogenic factors was determined using a commercial array kit. Release of each
molecule induced by individual galectins is expressed as fold increase over unstimulated controls (n = 2). B) HMEC-1 were preincubated with anti-
EGFR antibody (20 mg/ml) or irrelevant IgG during 30 min. Then, cells were incubated for 18 h with EGF (20 ng/ml) or with supernatants from
unstimulated or galectin-stimulated platelets. Endothelial cell proliferation and tube formation were analyzed (n = 3; *P,0.05 vs. unstimulated, #P,
0.05 vs. without neutralizing antibody (Ab)).
doi:10.1371/journal.pone.0096402.g005
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(SB203580), PKC (Go¨6983), Src (PP1), and pERK (U0126). To
examine possible inhibitory or synergistic effects of these
compounds, platelet activation was induced using the EC50 of
each galectin. Whereas release of VEGF mediated by Gal-8 was
partially prevented in platelets that were pretreated with inhibitors
of COX-1, PKC, p38 and Src kinases, Gal-1-induced secretion of
this proangiogenic factor was inhibited through blockade of PKC
and ERK phosphorylation. Moreover, Gal-3-induced VEGF
secretion was only prevented upon PKC blockade (Figure 3).
Treatment of platelets with aspirin partially inhibited VEGF
release triggered by Gal-8 but had no effect on VEGF release
induced by Gal-1 or Gal-3 (Figure 3). With regard to endostatin
release mediated by Gal-8, it was only slightly decreased in the
presence of PKC, Src and ERK inhibitors. Of note, Gal-1 and
Gal-3 still failed to induce endostatin secretion in the presence of
these inhibitors, excluding the possibility that any of these
pathways could interfere with endostatin release.
Platelet Stimulation by Galectins Promotes Angiogenic
Responses
To evaluate the functional impact of galectin effects, we next
assessed the angiogenic potential of conditioned medium gener-
ated by stimulation of platelets with each individual galectin.
Whereas supernatants derived from resting platelets showed no
significant effect, supernatants from platelets stimulated with Gal-
1,-3 or -8 elicited endothelial cell proliferation and capillary-like
tube formation (Figure 4). As previous studies indicated that all
three galectins have a direct proangiogenic activity [23,24,25,26],
it is conceivable that a variable amount of unbound galectin
present in platelet supernatants could be responsible for the
observed proangiogenic effect. To rule out this possibility, the
assays were repeated in the presence of the galectin competitor
lactose. Although lactose effectively blocked the direct stimulatory
effect of the three galectins on endothelial cell proliferation and
tubule formation (Figure S1), it failed to alter responses triggered
by supernatants from galectin-treated platelets, indicating that,
under our experimental conditions, the proangiogenic effects were
independent of a direct action of these lectins (Figure 4).
Altogether, these data demonstrate that although Gal-1, -3 or -8
differ in the pattern of secretion of pro- and antiangiogenic factors,
conditioned medium generated after platelet stimulation with any
of these three lectins clearly stimulated angiogenic responses. It is
well known that platelet-derived VEGF is one of the most
abundant molecules in ischemic tissues and plays a leading role in
revascularization; however we recently found that platelet-induced
angiogenesis triggered by thrombin is independent of VEGF [30].
To test the role of this factor in angiogenesis mediated by galectin-
treated platelets, we performed the same experiments in the
presence of anti-VEGFR2 or VEGF-A neutralizing antibodies. As
shown in Figure 4, cellular proliferation and tubule formation
induced by VEGF alone were fully inhibited by these antibodies
(96–99% of inhibition). However, when these angiogenic respons-
es were induced by platelets supernatants, only a slight inhibitory
effect was observed by either VEGFR2 or VEGF-A blockade (20–
25% of inhibition) (Figure 4). Thus, in spite of the considerable
increase in VEGF secretion triggered by galectins, the proangio-
genic effects triggered by galectin-treated platelets appear to be, at
least in part, independent of VEGFR2 signaling.
Pattern of Pro- and Antiangiogenic Molecules Secreted
by Platelets in Response to Gal-1, -3 and -8
As angiogenesis induced by supernatants from galectin-treated
platelets appears to be mostly VEGF-independent, we then
analyzed the pattern of secretion of platelet-derived angiogenic
factors triggered by Gal-1, -3 or -8 using an angiogenic microarray
kit (Figure 5 and Table S1). Factors increasing at least 1.5 fold
were included in the analysis. Remarkably, epidermal growth
factor (EGF) was the major factor released upon platelet
stimulation by the three galectins. The amounts of other factors
including PDGF-BB, angiogenin and VEGF, were equivalent in
supernatants from platelets treated with either Gal-1, -3 or -8,
whereas secretion of other factors was selectively modulated by
each individual galectin. While Gal-1 induced maximal release of
IL-6 and MMP-1, Gal-3 induced maximal release of I-308, IL-1b
and MMP-9 (Figure 5). Moreover, supernatants of platelet
stimulated by Gal-8 contained more EGF, ENA-78, bFGF,
GRO, TIMP-2, IFN-c, and endostatin than those from platelets
stimulated by Gal-1 or -3 (Figure 5). Altogether these findings
suggest that each galectin differentially controls the release of
platelet-derived angiogenic factors, which may act in concert to
promote angiogenesis.
To further identify the relevant mediator responsible for the
proangiogenic activity of platelets, angiogenic responses were
induced by platelet supernatants that were previously stimulated
with galectins in the presence of an anti-EGF receptor antibody.
Similar to VEGF, blockade of EGF activity resulted in moderate
inhibition of both endothelial cell proliferation and capillary-like
tube formation (Figure 5B). Moreover, simultaneous suppression
of VEGF and EGF, did not exert additive or synergic inhibitory
effects in platelet-mediated angiogenesis (Figure S2), suggesting
that the combined action of other factors accounts for the observed
effect.
Discussion
In this study we provide evidence of an additional mechanism,
i.e. the release of platelet-derived angiogenic molecules, by which
galectins promote angiogenesis. Although non-structurally related
galectins such as Gal-1, -3 and -8 selectively modulated secretion
of VEGF and endostatin from platelet a-granules, platelet
activation induced by each galectin resulted in a VEGF-
independent proangiogenic response, which was likely due to the
combined action of several angiogenic mediators.
The ability of all three galectins to trigger VEGF release, but
only Gal-8 being able to induce endostatin secretion is in
agreement with the new paradigm of platelet a-granule secretion.
This new paradigm supports the notion that not all a-granules are
morphologically similar, they store different cargo proteins, and
they can be selectively activated to release molecules with opposite
roles. Recent studies have focused on this novel paradigm in terms
of secretion of pro- and antiangiogenic molecules triggered by
agonists such as thrombin receptor agonists, ADP or thromboxane
A2 [5,7,8,9,10]. Here we demonstrate that the differential release
of VEGF or endostatin is not restricted to classical platelet agonists
but can also be induced by non-canonical platelet activators such
as galectins. Although the structure and dynamics of a-granule
secretion is still under debate, different hypotheses seem to
converge in the notion that selective signaling pathways might be
involved in the regulation of a-granule content exocytosis. In this
sense, differences in the release of pro- and antiangiogenic
molecules induced by galectins were not associated with differ-
ences in the kinetics of secretion or to structural divergences, but
rather with distinct signaling pathways triggered by each galectin.
While Gal-1 triggered PKC and ERK activation to induce VEGF
release, Gal-3 activated a PKC-dependent pathway to stimulate
the same biological response. On the other hand, release of VEGF
Angiogenesis Mediated by Galectin-Treated Platelets
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by Gal-8 required not only the activation of COX-1 but also
activation of PKC, p38, and Src kinases.
Interestingly, conditioned media derived from platelets activat-
ed by each galectin all elicited endothelial cell proliferation and
capillary-tube formation, two cellular events linked to angiogen-
esis. These data indicate that regardless of the differential effect of
Gal-1, -3 or -8 on the secretion of angiogenic factors, galectin-
induced platelet activation results in promotion of an angiogenic
phenotype.
In contrast to the traditional role of VEGF in platelet-mediated
angiogenesis, we found that suppressing VEGF signaling using
anti-VEGFR2 or anti-VEGF-A antibodies, did not considerably
alter endothelial cell responses, suggesting that this factor could be
dispensable for the angiogenic activity of platelets when activated
in response to galectin stimulation. Interestingly, we found that
blockade of EGF, the mayor angiogenic factor released from
platelets upon stimulation with galectins partially inhibited
angiogenesis mediated by supernatants from galectin-stimulated
platelets. Moreover, a similar degree of inhibition was observed
when the activity of both VEGF-A and EGF was inhibited. These
results suggest that the angiogenic activity mediated by platelets is
a complex process that appears to be due to the combined activity
of several angiogenesis-related molecules released from galectin-
stimulated platelets. In this regard, we recently demonstrated that
platelet-induced angiogenesis by thrombin also involves the
activity of several angiogenic modulators but not VEGF [30].
Altogether, these studies suggest that platelets can release pro- and
antiangiogenic substances and different agonists can selectively
regulate this process. Moreover, it could be speculated that in the
activated normal or tumor endothelium galectins are differentially
regulated [31,32,33] and contribute to tumor vascularization by
stimulating the release of diverse proangiogenic mediators.
Interestingly, the net biological effect appears to be proangiogenic
regardless of the platelet agonist used. This implies that the
proangiogenic effect of galectins via platelets contributes to a
positive feedback that influences tumor progression. However, we
do not rule out the possibility that, in an alternative pathologic
setting the contribution of platelet-derived antiangiogenic media-
tors might gain relevance. In this sense, it has been demonstrated
that concentration of angiogenesis regulatory proteins in platelets,
although relatively constant and stable under physiologic condi-
tions, is substantially modified by the presence of a growing tumor.
Specifically it has been shown that changes in major platelet
antiangiogenic factors such as platelet-associated PF-4 [34] and
TSP-1 [35] are upregulated in platelets of tumor-bearing mice.
Regarding TSP-1, this phenomenon has been found to be a
consequence of both, increased levels of TSP-1 mRNA in
megakaryocytes, as well as increased numbers of these cells in
the bone marrow of tumor-bearing mice [35]. Thus, it has been
suggested that the production and delivery of antiangiogenic
molecules by platelets might serve as a critical early host response
to suppress vascular supply during tumor growth, emphasizing the
potential value of these molecules as indicators for tumor growth
and regression. Since the early antiangiogenic response triggered
by platelets could be overcome during tumor progression inducing
a switch toward a platelet proangiogenic phenotype, more data are
needed to establish whether the platelet proteome changes after
longer periods following the establishment of a tumor. Supporting
these findings, it has been recently demonstrated that the tumor
cell line MCF-7 and the platelet agonist ADP, induce the release of
VEGF but not endostatin from platelets, thus promoting migration
and tubulogenesis in endothelial cells [9]. In addition, conditioned
medium from MCF-7-stimulated platelets contain a greater
number of proangiogenic factors compared to conditioned
medium from ADP-stimulated platelets suggesting that the process
of platelet activation with MCF-7 cells involves activation of
additional mechanisms rather than just ADP [9]. As MCF-7 cells
express several members of the galectin family, including Gal-1, -3
and -8 [36], and GPIIb/IIIa and GPIb are essential for
transducing galectin signaling [20,22], platelet activation mediated
by galectins could have evolved as a mechanism complementary to
ADP to promote a tumor proangiogenic phenotype.
In summary, our data highlight an additional mechanism, based
on the secretion of platelet-derived angiogenic factors, by which
galectins contribute to angiogenesis. As galectins are up-regulated
in endothelial cells and tumors in angiogenic-related disorders,
and galectin stimulation activates platelets to secrete soluble
proangiogenic factors, selective targeting of these pathways may
contribute to delineate novel therapeutic approaches in order to
promote tissue regeneration and attenuate atherosclerosis, ische-
mic ulcers, diabetes and cancer.
Supporting Information
Figure S1 Lactose inhibits endothelial cell proliferation
and capillary-like tube formation induced by galectins.
A) HMEC-1 (2.56104/well) were preincubated in 48-well plates in
the presence of lactose (50 mM) for 30 min. Then, cells were
incubated in buffer Tyrode’s with or without VEGF-A (20 ng/ml)
(positive control) or with Gal-1, -3 or -8 at the indicated
concentrations. After 18 h of incubation, MTT reagent was
added to each well. Reaction was stopped and the absorbance was
determined at 570 nm (n= 3; *P,0.05 vs. unstimulated). B)
HMEC-1 (2.56104) were preincubated in Matrigel-coated wells in
the presence of lactose for 30 min. Then, cells were incubated with
VEGF-A (positive control) or with Gal-1, -3 or -8 at the indicated
concentrations for 18 h. Tube formation was analyzed under an
inverted light microscope and the number of branch points was
determined in four non-overlapping fields (n = 3; *P,0.05 vs.
unstimulated).
(TIF)
Figure S2 Roles of VEGF and EGF in angiogenesis
induced by galectin-stimulated platelets. HMEC-1 were
preincubated in 48-well plates with anti-VEGF-A (2 mg/ml), anti-
EGFR (20 mg/ml), or irrelevant mouse and rabbit IgG controls
during 30 min. Since proliferation or capillary tube formation
were not modify by the different IgGs we only show the values
obtained in the absence of antibodies (none). Then, cells were
incubated during 18 h with VEGF (20 ng/ml) and EGF (20 ng/
ml) (positive controls), or with supernatants from unstimulated or
galectin-stimulated platelets. A) Endothelial cell proliferation was
determined by addition of MTT reagent. B) Tube formation in
Matrigel-coated wells was analyzed under an inverted light
microscope, and the number of branch points in four non-
overlapping fields was determined. The photographs show one
individual field of endothelial cells incubated with supernatants
from Gal-1-stimulated platelets (n = 3; *P,0.05 vs. unstimulated,
#P,0.05 vs. without neutralizing antibodies (Abs)).
(TIF)
Table S1 Platelet-derived angiogenesis modulators
measured by the Antibody Array G Series 1000 from
Raybiotech (n=2).
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